6th Dec 2019 16:10
Block Listing Six Monthly Return
6 December 2019
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Date: 6 December 2019
Name of applicant: | Futura Medical Plc | |||
Name of scheme: | Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme | |||
Period of return: | From: | 1 June 2019 | To: | 30 November 2019 |
Balance of unallotted securities under scheme(s) from previous return: | 6,225,000 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | n/a | |||
Less: Number of securities issued/allotted under scheme(s) during period: | n/a | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 6,225,000 | |||
Number and class of securities originally admitted and the date of admission | USOS Total: 3,882,912 814,424 25 May 2011 1,202,280 8 October 2013 1,466,208 25 May 2017 400,000 30 May 2018
USIS Total: 425,000 425,000 30 November 2018
EMI Total: 7,012,088 1,520,576 25 May 2011 1,467,720 8 October 2013 1,893,792 25 May 2017 790,000 30 May 2018 1,340,000 30 November 2018 | |||
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO
Email: [email protected]Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: [email protected]
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Related Shares:
Futura Medical